Active, not recruitingPhase 2NCT05945823
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Studying Squamous cell carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taiho Oncology, Inc.
- Intervention
- Futibatinib(drug)
- Enrollment
- 53 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (22)
- University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States
- Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Henry Ford Health System, Detroit, Michigan, United States
- The Minniti Center - Medical Oncology and Hematology, Mickleton, New Jersey, United States
- Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI)), Buffalo, New York, United States
- NYU Langone, New York, New York, United States
- Gabrail Cancer Center Research LLC, Canton, Ohio, United States
- Alliance Cancer Specialists, Horsham, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Dallas VA Medical Center, Dallas, Texas, United States
- Inova Schar Cancer Institute, Fairfax, Virginia, United States
- Blue Ridge Cancer Care, Roanoke, Virginia, United States
- Virginia Mason Medical Center, Seattle, Washington, United States
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05945823 on ClinicalTrials.govOther trials for Squamous cell carcinoma of pancreas
Additional recruiting or active studies for the same condition.